FDA vs. Cheerios: The Weirdest Battle in History?
The Motley Fool's health-care show Market Checkup focuses this week on cholesterol, one of America's most notable health-care concerns.
According to the CDC, approximately 71 million Americans have high cholesterol, and less than 50% actually get treated. High levels of LDL cholesterol, commonly known as "bad" cholesterol, can lead to dangerous health problems, including heart disease and high blood pressure. In this week's show, health-care analysts David Williamson and Max Macaluso discuss the leading cholesterol drugs on the market and in development, but they kick off their discussion with a look back at one of the strangest battles in history: FDA vs. Cheerios.
In 2009, the FDA sent a letter to General Mills warning that marketing Cheerios as a product that could lower cholesterol meant that the popular breakfast cereal would have to go through the drug approval process. While investors weren't worried by the news (looking at historical prices, shares of General Mills were about flat after the warning letter became public), and the company was able to sort out this problem, it certainly helped the FDA distinguish between foods and drugs that have a proven therapeutic benefit.
Your financial health is just as important as your personal health. The Motley Fool's special free report "3 Stocks That Will Help You Retire Rich" names specific investment opportunities that could help you build long-term wealth and help you retire well. The Fool also outlines critical wealth-building strategies that every investor should know. Click here to keep reading.
The article FDA vs. Cheerios: The Weirdest Battle in History? originally appeared on Fool.com.David Williamson, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.